Physician profile
Charlene E Borja
NPI 1902952591
$5,118.33
in general payments reported to CMS, 2019-2025
40 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $1,001 · 2021: $1,744 · 2022: $952 · 2023: $571 · 2024: $356 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,189.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,396.16 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $499.42 | 2019-2023 | Mounjaro |
| Pfizer INC. | $388.63 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $311.19 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $301.15 | 2020-2022 | |
| Allergan, INC. | $268.60 | 2020-2022 | |
| Antares Pharma, INC. | $241.47 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Eisai INC. | $199.66 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.61 | 2020-2022 | |
| Astellas Pharma US INC | $117.28 | 2020-2024 | Veozah |
| Glaxosmithkline, LLC. | $108.41 | 2020-2025 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $95.08 | 2021-2024 | Gardasil 9, Gardasil |
| Novo Nordisk INC | $92.70 | 2020-2025 | |
| Horizon Therapeutics Plc | $74.55 | 2021-2022 | |
| Hologic Sales and Service, LLC | $73.57 | 2022-2025 | Thinprep 2000 Processor, Aptima |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charlene Borja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.